Author
Listed:
- Federico Cosenz
- Francesca De Domenico
Abstract
PurposeThis paper develops a systemic framework for investment decision-making in pharmaceutical and biotech companies, addressing growing complexity driven by regulatory uncertainty, technological disruption, and evolving market needs. It seeks to move beyond traditional, fragmented approaches toward more integrated and viable innovation strategies.Design/methodology/approachThe study adopts a systemic perspective that combines risk management, strategic partnerships and technological enablers such as artificial intelligence and predictive analytics. Drawing on case studies from AstraZeneca and Eli Lilly, as well as on notable failures such as Pfizer's torcetrapib and repeated setbacks in Alzheimer's research, the analysis illustrates how systemic approaches enhance portfolio resilience and decision quality through cross-functional governance.FindingsThe findings demonstrate that a systemic model built around four interrelated pillars – scientific merit, regulatory feasibility, commercial viability and competitive positioning – supports better risk-adjusted decisions and stronger alignment between R&D, financial, and strategic functions. By integrating these dimensions, organizations can improve the robustness of their investment portfolios and foster long-term innovation capability.Originality/valueThis study contributes a novel conceptual and practical framework that links strategic intelligence, technological tools and governance mechanisms in the investment decision-making process. It offers actionable insights for managers, investors, and policymakers seeking to align capital allocation with sustainable innovation. By adopting systemic approaches, pharmaceutical and biotech firms can transition from reactive, fragmented decision-making toward proactive, evidence-based strategies that optimize risk-adjusted returns and accelerate the delivery of transformative therapies.
Suggested Citation
Federico Cosenz & Francesca De Domenico, 2026.
"Beyond fragmented strategy choices: a systemic approach to support R&D investment in pharma and biotech companies,"
European Journal of Innovation Management, Emerald Group Publishing Limited, vol. 29(11), pages 225-253, April.
Handle:
RePEc:eme:ejimpp:ejim-10-2025-1382
DOI: 10.1108/EJIM-10-2025-1382
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eme:ejimpp:ejim-10-2025-1382. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Emerald Support (email available below). General contact details of provider: .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.